Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer"
- PMID: 36379839
- DOI: 10.1016/j.ejca.2022.10.007
Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer"
Comment in
-
Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer".Eur J Cancer. 2023 Jan;179:149-151. doi: 10.1016/j.ejca.2022.10.008. Epub 2022 Nov 9. Eur J Cancer. 2023. PMID: 36371304 No abstract available.
Comment on
-
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.Front Mol Biosci. 2022 Mar 15;9:834651. doi: 10.3389/fmolb.2022.834651. eCollection 2022. Front Mol Biosci. 2022. PMID: 35372498 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
